Mirosław M.
- Country
- Poland
- Department
- N/A
Research Overview
- Evaluation of Long-term Safety, Tolerability, and Efficacy of Zasocitinib (TAK-279) in Patients with Moderate-to-Severe Plaque Psoriasis
- Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of ESK-001 and Apremilast in Moderate to Severe Plaque Psoriasis Patients
- Long-term Safety, Efficacy, and Response Durability of Envudeucitinib in Moderate to Severe Plaque Psoriasis: An Extension Study
Data & Insights
Has run more than one trial at 114 of 204 partner sites.
Specializations
Dermatological Research
This clinical investigator specializes in the treatment of moderate to severe plaque psoriasis, conducting extensive research into innovative therapeutic approaches for this chronic skin condition.
- Chronic inflammatory skin disorders
- Advanced psoriasis management
- Long-term treatment outcomes
Their research encompasses evaluating novel oral medications and investigating therapeutic durability in dermatological conditions.
Clinical Safety Studies
The investigator focuses on comprehensive safety and tolerability assessments of emerging treatments, particularly in the context of extended therapeutic applications.
- Long-term safety monitoring
- Treatment tolerability evaluation
- Therapeutic risk assessment
Their work includes systematic evaluation of treatment responses and safety profiles in chronic conditions.
Therapeutic Efficacy
The investigator conducts research on comparative therapeutic effectiveness, examining various treatment modalities for inflammatory skin conditions.
- Treatment response analysis
- Therapeutic durability assessment
- Clinical outcome evaluation
Their research includes analysis of treatment effectiveness across different therapeutic approaches.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.